COVAX announces additional deals to access promising COVID-19 vaccine candidates

COVAX has guaranteed access to a portion of the first wave of production, followed by volume scales as further supply becomes available

COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income level, yesterday announced that it had arrangements in place to access nearly two billion doses of COVID-19 vaccine candidates, on behalf of 190 participating economies. For the vast majority of these deals, COVAX has guaranteed access to a portion of the first wave of production, followed by volume scales as further supply becomes available. The arrangements announced yesterday will enable all participating economies to have access to doses in the first half of 2021, with first deliveries anticipated to begin in the first quarter of 2021 – contingent upon regulatory approvals and countries’ readiness for delivery.

Given these are arrangements for 2 billion doses of vaccine candidates which are still under development, COVAX will continue developing its portfolio: this will be critical to achieve its goal of securing access to 2 billion doses of safe and effective, approved vaccines that are suitable for all participants’ contexts, and available by the end of 2021. However, yesterday’s announcements offer the clearest pathway yet to end the acute phase of the pandemic by protecting the most vulnerable populations around the world. This includes delivering at least 1.3 billion donor-funded doses of approved vaccines in 2021 to the 92 low- and middle-income economies eligible for the COVAX AMC.

The new deals announced include the signing of an advance purchase agreement with AstraZeneca for 170 million doses of the AstraZeneca/Oxford candidate, and a memorandum of understanding (MoU) with Johnson & Johnson for 500 million doses of the Janssen candidate, which is currently being investigated as a single dose vaccine.. These deals are in addition to existing agreements COVAX has with the Serum Institute of India (SII) for 200 million doses – with options for up to 900 million doses more – of either the AstraZeneca/Oxford or Novavax candidates, as well as a statement of intent for 200 million doses of the Sanofi/GSK vaccine candidate.

In addition to this, COVAX also has – through R&D partnership agreements – first right of refusal in 2021 to access potentially more than one billion doses (based on current estimates from the manufacturing processes under development) that will be produced, subject to technical success and regulatory approval, by candidates in the COVAX R&D Portfolio.

“This commitment is evidence that the world learned an important lesson from the 2009 H1N1 pandemic. Our research and development efforts have begun to pay off. We now have safe and effective vaccines that can protect against COVID-19 and a clear pathway to securing 2 billion doses for the populations at greatest risk all around the world,” said Dr Richard Hatchett, CEO of the Coalition for Epidemic Preparedness Innovations (CEPI).

“Securing the right of first refusal of successful vaccine production as part of R&D arrangements has helped guarantee equitable access to vaccines, a founding principle of CEPI. The challenge of delivering the vaccines that have demonstrated success, of completing the development of other promising vaccine candidates to further increase supply, and of ending the acute phase of the pandemic, lies ahead of us.”

Alongside boosting its pathway to two billion doses of approved vaccines through direct agreements with manufacturers, the COVAX Facility has also opened another potential source of vaccines. Published today, the Principles for Dose-Sharing provide a framework for higher-income economies to make additional volumes secured via bilateral deals available through the Facility primarily to AMC participants, on an equitable basis. These principles outline that such doses must be safe and effective, available as early as possible and should be available in substantive volumes as early as possible in 2021 to enable rapid and flexible deployment by the Facility – supporting the overall goal of equitable access.

Tags : #COVIDVaccine #AstraZeneca #COVID-19Pandemic

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-




Trending Now

Dr. Jitender Aggarwal, Founder, and CEO, Sarthak Educational Trust presses on the need for the Government to spend more on HealthcareJanuary 25, 2021
‘’Digital consultation does not have the same impact as the physical ones,’’ says Kishor Dharmy, Personal Fitness trainerJanuary 25, 2021
Making visually impaired and blind “Atma-Nirbhar” is a challenge for India - P.V.M Rao, Faculty Member, IIT DelhiJanuary 25, 2021
Fitness of the body and mind should be a constant goal says Ishani Pimpalkhare, Freelance Yoga InstructorJanuary 25, 2021
25 millions Covid-19 cases in US, UK strain more deadly says CDCJanuary 25, 2021
India reports 13,203 fresh coronavirus cases, 131 deaths; caseload at 1.06 croreJanuary 25, 2021
India reports 13,203 fresh coronavirus cases, 131 deaths; caseload at 1.06 croreJanuary 25, 2021
India reports 13,203 fresh coronavirus cases, 131 deaths; caseload at 1.06 croreJanuary 25, 2021
Cumulative number of vaccinated healthcare workers across the country more than 16 lakhJanuary 25, 2021
More than 16 lakh people administered Covid-19 vaccines in country so far: GovtJanuary 25, 2021
There is no magic formula or easy, quick fix, but it requires consistency and effort - Shameera Somani, Masters in Food Science and NutritionJanuary 25, 2021
Decoding the best ways to lose weight with Parul Malhotra Bahl, Founder, Diet ExpressionJanuary 23, 2021
Zydus Cadila receives final approval from USFDA for Liothyronine Sodium TabletsJanuary 23, 2021
Braille can be complemented by technology and not necessarily replaced says Ketan Kothari, Manager – Advocacy, Sightsavers IndiaJanuary 23, 2021
’50 – 60% of the population have uncontrolled blood sugar levels,’’ says Dr. Abhijit Bhograj, Co-founder and CMO, 7 SugarJanuary 23, 2021
Govt. uses Rapid Assessment System, RAS for taking feedback from people vaccinated for COVID-19January 23, 2021
Cumulative number of vaccinated Healthcare Workers across the country has surpasses 12.7 lakh January 23, 2021
India's coronavirus count increases by 14,256 fresh cases; 152 deaths reported in 24 hrsJanuary 23, 2021
Pfizer and BioNTech reach agreement with COVAX for advance purchase of Vaccine to Help Combat COVID-19January 23, 2021
In life, there are no shortcuts says Honnesh Kamaria, Yoga and Fitness Instructor, TheYogaShrineJanuary 22, 2021